← All trials
NCT02669459
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2016
- Primary completion
- Mar 1, 2018
- Completion date
- Mar 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 433
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Erasmus University RotterdamLead sponsor
- Maastricht UniversityCollaborator
- Albert Schweitzer HospitalCollaborator
- Sint Franciscus GasthuisCollaborator
- Meander Medical CenterCollaborator
- Erasmus University RotterdamOverall official - principal investigator
- Erasmus University RotterdamReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.